These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33803078)

  • 1. Utilizing Immunocytokines for Cancer Therapy.
    Runbeck E; Crescioli S; Karagiannis SN; Papa S
    Antibodies (Basel); 2021 Mar; 10(1):. PubMed ID: 33803078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The present and future of immunocytokines for cancer treatment.
    Gout DY; Groen LS; van Egmond M
    Cell Mol Life Sci; 2022 Sep; 79(10):509. PubMed ID: 36066630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine/Antibody Fusion Protein Design and Evaluation.
    Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
    Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15R
    Chen J; Shen Z; Jiang X; Huang Z; Wu C; Jiang D; Yin L
    Antib Ther; 2023 Jan; 6(1):38-48. PubMed ID: 36683766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
    Neri D
    Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
    Hess C; Neri D
    Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
    Hutmacher C; Neri D
    Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity.
    Gillies SD
    Protein Eng Des Sel; 2013 Oct; 26(10):561-9. PubMed ID: 24025193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytokines: a promising approach to cancer immunotherapy.
    Lode HN; Xiang R; Becker JC; Gillies SD; Reisfeld RA
    Pharmacol Ther; 1998 Dec; 80(3):277-92. PubMed ID: 9888698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
    Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
    Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
    Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
    Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytokines: a new approach to immunotherapy of melanoma.
    Reisfeld RA; Becker JC; Gillies SD
    Melanoma Res; 1997 Aug; 7 Suppl 2():S99-106. PubMed ID: 9578424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.
    Tzeng A; Kwan BH; Opel CF; Navaratna T; Wittrup KD
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3320-5. PubMed ID: 25733854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.
    Prodi E; Neri D; De Luca R
    Onco Targets Ther; 2024; 17():697-715. PubMed ID: 39224695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Cytokine Delivery for Cancer Treatment: Engineering and Biological Effects.
    Rybchenko VS; Aliev TK; Panina AA; Kirpichnikov MP; Dolgikh DA
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors.
    Corbellari R; Nadal L; Villa A; Neri D; De Luca R
    Anticancer Drugs; 2020 Sep; 31(8):799-805. PubMed ID: 32304410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.
    Murer P; Neri D
    N Biotechnol; 2019 Sep; 52():42-53. PubMed ID: 30991144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.